MedTrace Logo

Daily Avanafil for Erectile Dysfunction

NCT04374994 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-09-16

No results posted yet for this study

Summary

In this study, the investigators tried to study the effect of daily avanafil on the serum level of endothelial function markers, as well as its impact on the erectile function in males with erectile and endothelial dysfunction by comparing the results with controls who received placebo.

Conditions

Interventions

DRUG

Avanafil 50 MG

Oral phosphodiesterase type 5 inhibitors

DRUG

Placebo oral tablet

lactose and maize starch, Egypt

Sponsors & Collaborators

  • University of Alexandria

    lead OTHER

Principal Investigators

  • Abdelaal Elkamshoushi, MD · University of Alexandria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2019-04-15
Completion
2019-10-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04374994 on ClinicalTrials.gov